Influenza Countermeasure Program
Influenza
Not SpecifiedActive
Key Facts
About DynPort Vaccines
DynPort Vaccine Company (DVC) is a U.S.-based government services contractor specializing in the development and licensure of vaccines and therapeutics for biodefense and public health emergencies. Operating as part of GDIT, it provides end-to-end program management, regulatory strategy, clinical research, and manufacturing oversight for complex government-funded medical countermeasure programs. With over two decades of experience, DVC has a proven track record in navigating the FDA regulatory pathway, including submissions under the Animal Rule, and serves as a critical partner for federal agencies in protecting military and civilian populations.
View full company profileOther Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| PanCytoVir™ (oral probenecid) | TrippBio | IND Submitted |
| Mimotopes-004 | Mimotopes | Preclinical |
| Next-Gen / Universal Flu Vaccines | CSL Seqirus | Research / Early Clinical |
| Oseltamivir 75 mg | MSN Laboratories | Commercial |
| AI Programme - Influenza | Poolbeg Pharma | Discovery |
| Influenza Antibodies | new/era/mabs | Research/Pre-clinical |
| Influenza Vaccine | Medigen | Preclinical |
| Nasal Influenza Vaccine | Abera Bioscience | Pre-clinical |
| Zapnometinib (ATR-002) | Atriva Therapeutics | Phase 2 |
| EV25 | Eradivir | Pre-clinical |
| Not Specified | New Amsterdam Sciences | Pre-clinical |
| Influenza Program | Arisan Therapeutics | Preclinical |